Eli Lilly and Co.

23. Okt. 2026, 20:02 UTC

Eli Lilly and Co shares are declining, continuing a downward trend since Thursday's close, while the broader Pharmaceuticals sector is also lower.

22. Okt. 2026, 20:07 UTC

Eli Lilly breaks ground on a $5 billion manufacturing facility in Virginia, expected to create 650 permanent jobs and support U.S. manufacturing initiatives.

21. Okt. 2026, 20:07 UTC

Leerink Partners raised Eli Lilly's price target to $1.32k, while RBC Capital set a target of $1.5k, but shares are declining in today's session.

20. Okt. 2026, 23:02 UTC

Eli Lilly named RBC Capital's preferred pharmaceutical stock with a $1.5K price target, despite shares declining modestly in after-market hours.

19. Okt. 2026, 23:06 UTC

Eli Lilly announces positive Phase 3 SHINE-2 study results for Omvoh in pediatric ulcerative colitis, with 81% of participants achieving clinical response at Week 12.

17. Okt. 2026, 00:01 UTC

Eli Lilly and Co shares are lower in after-market hours, reflecting broader market declines amid stronger-than-expected inflation metrics and significant inflows in U.S. TIC Flows.

16. Okt. 2026, 23:06 UTC

Eli Lilly and Co shares are trading slightly lower in after-market hours, reflecting routine fluctuations amid a stable broader market context.

15. Okt. 2026, 23:11 UTC

Eli Lilly announces new data showing treatment goals achieved for ulcerative colitis and Crohn's disease patients with Omvoh after one year.

14. Okt. 2026, 23:42 UTC

Eli Lilly and Co's shares are trading lower in after-market hours, reflecting a broader market decline amid rising Treasury yields and inflation concerns.

13. Okt. 2026, 20:02 UTC

Eli Lilly announces a clinical trial collaboration with Prelude Therapeutics for a Phase 1 trial involving abemaciclib and imlunestrant, contributing to bearish sentiment.

12. Okt. 2026, 20:07 UTC

Eli Lilly gains support as RBC Capital reiterates Outperform rating with a $1.5K price target, following new data from the TOGETHER-PsO Phase 3b trial.

9. Okt. 2026, 20:07 UTC

Eli Lilly presents new data from its Phase 3b TOGETHER-PsO trial, showing significant biomarker changes with the combination of Taltz and Zepbound for psoriasis treatment.

8. Okt. 2026, 23:05 UTC

Eli Lilly and Co shares are trading lower in after-market hours, reflecting a decline since Thursday's close and fluctuating near the lower end of its recent range.

7. Okt. 2026, 23:06 UTC

Eli Lilly and Co is trading slightly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month trading range.

6. Okt. 2026, 20:07 UTC

Eli Lilly contributed to a $120 million Series B funding round for General Medicine, raising total funding to $152 million, amid positive market sentiment.

5. Okt. 2026, 23:06 UTC

Eli Lilly and Co is gaining after-hours as it plans to present new dermatology data at the 2026 Fall Clinical Dermatology Conference in October.

2. Okt. 2026, 20:07 UTC

Eli Lilly shares fell amid FDA approval of Jaypirca for chronic lymphocytic leukemia, which includes serious safety warnings, impacting market sentiment.

1. Okt. 2026, 23:06 UTC

Eli Lilly and Co is seeing a slight upward move in after-market trading, with prices fluctuating around the middle of its one-month trading range.

30. Sept. 2026, 23:06 UTC

Eli Lilly's shares rose in after-market hours following positive Phase 3 ACHIEVE-4 trial results for Foundayo, showing lower cardiovascular risks compared to insulin glargine.

28. Sept. 2026, 19:16 UTC

Eli Lilly's Olumiant receives expanded FDA approval for treating severe alopecia areata in adolescents, boosting market potential as shares rise modestly.

25. Sept. 2026, 20:08 UTC

Eli Lilly faces negative sentiment after a jury ruled it breached a licensing agreement, resulting in a $90 million damages award, while shares remain roughly flat.

24. Sept. 2026, 20:03 UTC

Eli Lilly received FDA approval for Onswik, a weekly insulin for type 2 diabetes, and entered a $3.25 billion licensing agreement with InnoCare Pharma.

23. Sept. 2026, 23:05 UTC

Eli Lilly and Co's stock is roughly flat in after-market trading, remaining near the lower end of its one-month trading range since Wednesday's close.

22. Sept. 2026, 23:06 UTC

Eli Lilly's stock is higher in after-market trading as the company begins construction on a $6.5 billion facility for its oral GLP-1 drug, Foundayo.

21. Sept. 2026, 23:11 UTC

Eli Lilly has started construction on a $6.5 billion facility in Houston to produce its GLP-1 receptor agonist, Foundayo, creating over 600 permanent jobs.

16. Sept. 2026, 20:10 UTC

Ginkgo Bioworks partners with Eli Lilly's TuneLab to enhance biotech innovation, while Twist Bioscience provides antibody data services; shares are slightly higher.

15. Sept. 2026, 23:01 UTC

Eli Lilly shares are trading roughly flat after-market with no specific news. Broader market sentiment is impacted by a decline in the Empire State Manufacturing Index.

14. Sept. 2026, 23:06 UTC

Eli Lilly's Foundayo captures over 30% of new U.S. obesity patients, boosting shares higher in after-market hours amid strong demand for oral treatments.

10. Sept. 2026, 20:07 UTC

Eli Lilly shares are lower as HSBC maintains a Reduce rating and raises the price target to $940 amid ongoing challenges and sector decline.

9. Sept. 2026, 19:16 UTC

Eli Lilly received FDA approval for Mounjaro, enhancing its growth potential. Analysts maintain a favorable outlook as shares advance during Wednesday's session.